← All organizations
Highest phase reached
Phase 3
First clinical trial
Oct 15, 2019Last known activity
May 29, 2024
Acquired by AbbVie on Dec 7, 2023
Timeline
2010s
- Jan 1, 2018
Cerevel Therapeutics, LLC— Founded
2020s
- Dec 7, 2023
AbbVie— Acquired By
Drugs by trial phase (15 distinct, 37 trials)
Phase 3 (1 own, 0 via acquisition)
Phase 2 (4 own, 0 via acquisition)
Phase 1 (10 own, 0 via acquisition)
Indications
Recent trials (50)
- NCT06435923Lead sponsorPhase 1May 29, 2024
- NCT06366243Lead sponsorPhase 1May 10, 2024
- NCT06301971Lead sponsorPhase 1Mar 4, 2024
- NCT05965219Lead sponsorPhase 1Aug 15, 2023
- NCT05941442Lead sponsorPhase 2Jul 31, 2023
- NCT05940402Lead sponsorPhase 1Jul 24, 2023
- NCT05940402Study directorPhase 1Jul 24, 2023
- NCT05933187Lead sponsorPhase 1Jul 19, 2023
- NCT05935033Lead sponsorPhase 1Jun 30, 2023
- NCT05915546Lead sponsorPhase 1Jun 8, 2023
- NCT05824143Lead sponsorPhase 1Apr 17, 2023
- NCT05547542Lead sponsorPhase 1Dec 30, 2022
- NCT05610189Lead sponsorPhase 1Dec 15, 2022
- NCT05644977Lead sponsorPhase 1Dec 2, 2022
- NCT05581823Lead sponsorPhase 1Oct 19, 2022
Details
- Founded
- Boston, MA, US Jan 1, 2018
- Last known activity
- May 29, 2024